In the News | Citizen Health Press Highlights

“We have our own proprietary database that we have built from scratch over many years to pull together every single e-fax number, every single email for every health information management department or medical records department,” for every single provider or hospital institution in the U.S., Citizen CEO Farid Vij told ...

There was little hope only a few years ago of treatments for kids with ultrarare SLC13A5 or FOXG1 syndromes. Drug companies were loathe to take on the cost of discovering and developing therapies, much less expensive and risky clinical trials, for genetic conditions with only a couple hundred patients.

"We orchestrate Gemini 2.5 Flash and Gemini 2.5 Pro models within a LangGraph‑powered multi‑agent framework, ensuring the most relevant evidence reaches patients and caretakers without hallucinations." - Daniel Wang, CTO, Citizen Health

Healthcare data sharing is evolving rapidly across CMS, ONC, and the entire industry. In this first episode of InteropChat, we brought together four top experts to break down what's happening and what's next.

"It has been several years since I last wrote a blog post about SCN8A. A wide range of clinical presentations have been described since, and significant progress has been made towards understanding the disease mechanism. However, SCN8A-related disorders have not become less puzzling."

Together, the organizations will establish a partnership focused on neuromuscular disorders, including limb-girdle muscular dystrophies (LGMDs), Charcot-Marie-Tooth (CMT) disease, nemaline myopathy (NM), myotonic dystrophies, and related conditions.

On this episode, Tania Simoncelli (Vice President, Translational Impact and Engagement, Chan Zuckerberg Initiative) and Nasha Fitter (Co-founder & CBO, Citizen Health and Co-founder & CEO, FOXG1 Research Foundation) join forces to discuss how rare disease patient advocacy has transformed over time and how the biopharmaceutical industry should adapt to better meet the needs of today’s patients.

Citizen Health today announced a strategic partnership to support Rocket Pharmaceutical Inc.'s (Rocket Pharma) clinical and long-term data initiatives for arrhythmogenic cardiomyopathy (ACM) caused by mutations in the PKP2 gene.

Farid Vij, Co-founder and CEO at Citizen Health – We discussed advances in patient-level data access and re-defining practical precision-medicine to yield better patient outcomes. Health can be elusive for many patients, a complex "equation" with more than one answer, but RWD and AI are helping to solve this complexity.

The panel, featuring Craig Lipset from the Decentralized Trials & Research Alliance, Deirdre BeVard of CSL Innovation GmbH, Heidi Bjornson-Pennell from the Chan Zuckerberg Initiative (CZI), Nasha Fitter of Citizen Health, Craig Martin from the Orphan Therapeutics Accelerator, and Tracey Sikora from the National Organization for Rare Disorders (NORD), explored how patients are evolving from passive participants to active leaders in drug development.

With a vision rooted in compassion and innovation, Nasha Fitter continues to inspire change and hope for those navigating the challenges of rare diseases. Check out Nasha Fitter’s exclusive interview with Eqvista.

FirstWord reached out to three companies, each offering different healthtech and digital health solutions but whose technologies are wholly dependent on a robust AI infrastructure, to get their initial views on Stargate, what challenges might the project face and critical factors that would help it achieve success.